With close ties to University of Connecticut, LambdaVision isorganized around the design and development of an innovative, protein-based retinal implant that utilizes the light-activated protein, bacteriorhodopsin, to stimulate the retina of patients suffering from impaired vision or loss of sight due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP). Current treatments of RP and AMD only slow disease progression. LambdaVision is dedicated to creating a retinal prosthesis that is capable of restoring high-resolution vision and enhancing the quality of life for those afflicted by retinal degeneration.
